Vigamox Shortage: What Providers and Prescribers Need to Know in 2026

Ophthalmic antibiotic availability has become an increasingly common pain point for prescribers. Whether your patients are calling to report they can't fill their Vigamox prescription, or you're managing post-surgical prophylaxis in a high-volume surgical practice, understanding the current supply landscape is essential to maintaining continuity of care.

This briefing provides ophthalmologists, optometrists, primary care physicians, pediatricians, NPs, and PAs with the most current information on Vigamox (moxifloxacin ophthalmic 0.5%) availability, the clinical alternatives to consider, and practical tools to help patients get treatment without delay.

Current Vigamox Supply Status (2026)

As of 2026, moxifloxacin ophthalmic solution 0.5% (Vigamox) is NOT listed as an active shortage on the FDA Drug Shortages database or the ASHP drug shortage list. The brand-name product is distributed by Novartis Pharmaceuticals. Generic versions are available from multiple manufacturers including Teva, Alembic, and Bausch Health.

Despite this, your patients may still experience difficulty filling prescriptions. This is typically due to localized stocking gaps rather than a systemic manufacturing shortage. Contributing factors include:

Seasonal surges in bacterial conjunctivitis cases (back-to-school season, winter respiratory illness season)

Perioperative demand at practices with high cataract and refractive surgery volumes

Regional distributor inventory fluctuations

Variability in brand vs. generic stocking at individual pharmacies

Clinical Review: Vigamox (Moxifloxacin Ophthalmic 0.5%)

Moxifloxacin is a fourth-generation fluoroquinolone that exerts bactericidal activity through dual inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV. This dual mechanism confers broader gram-positive coverage compared to earlier fluoroquinolones such as ciprofloxacin and ofloxacin.

Key clinical advantages of moxifloxacin ophthalmic:

Preservative-free formulation: Contains no benzalkonium chloride (BAK) or other preservatives, reducing ocular surface toxicity. Important for post-surgical patients and those with pre-existing dry eye.

Three-times-daily dosing: More convenient than older agents requiring dosing every 2–4 hours, improving patient adherence.

Broad gram-positive coverage: Superior activity against S. aureus, S. pneumoniae, and streptococcal species compared to ciprofloxacin and ofloxacin.

Favorable safety profile: Systemic absorption after topical use is minimal (mean steady-state Cmax 2.7 ng/mL — approximately 1,600-fold lower than therapeutic oral doses). No systemic boxed warning applies to the ophthalmic formulation.

FDA-Approved Indications

Vigamox is indicated for bacterial conjunctivitis caused by susceptible strains including: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, S. epidermidis, S. haemolyticus, S. hominis, S. warneri, Streptococcus pneumoniae, S. viridans group, Acinetobacter lwoffii, Haemophilus influenzae, H. parainfluenzae, and Chlamydia trachomatis.

Therapeutic Alternatives by Clinical Scenario

When moxifloxacin ophthalmic is unavailable, consider the following alternatives based on clinical context:

Besifloxacin 0.6% (Besivance): Fourth-generation fluoroquinolone developed exclusively for ophthalmic use. Demonstrates potent in vitro activity against ciprofloxacin-resistant MRSA and MRSE. TID × 7 days dosing. No reported systemic use means lower resistance selection pressure.

Ciprofloxacin 0.3% (Ciloxan): Second-generation fluoroquinolone; widely available generic. Good gram-negative coverage. Less active against gram-positive cocci than moxifloxacin. Available as drops and ointment. Note: crystalline corneal deposits possible with drops.

Tobramycin 0.3% (Tobrex): Aminoglycoside; non-fluoroquinolone option. Preferred for Pseudomonas coverage in contact lens wearers. QID dosing. Generic widely available. Combination product (Tobradex) available if concomitant anti-inflammatory is needed.

Polytrim (Polymyxin B / Trimethoprim): Non-fluoroquinolone combination; inexpensive and widely stocked. Appropriate for mild-to-moderate conjunctivitis when fluoroquinolones are unavailable or contraindicated.

Azithromycin 1% (Azasite): Macrolide; BID × 2 days then QD × 5 days. Anti-inflammatory properties. Good option for pediatric patients or those who benefit from less frequent dosing.

Perioperative Prophylaxis Considerations

For practices relying on moxifloxacin for pre- and post-cataract or refractive surgery prophylaxis: if Vigamox is temporarily unavailable, besifloxacin or ciprofloxacin are common protocol substitutions. Some surgeons use povidone-iodine irrigation intraoperatively as the primary prophylactic measure and adjust topical antibiotic regimens accordingly.

Consider having patients pick up their perioperative drops in advance — 7–14 days before scheduled surgery — to avoid last-minute pharmacy access issues.

Helping Your Patients Find Vigamox in Stock

Your front-desk or clinical staff can recommend medfinder for providers to patients struggling to fill Vigamox prescriptions. medfinder calls pharmacies in the patient's area to check which ones have the medication in stock, then texts results to the patient. This significantly reduces "unable to fill" callbacks to your office.

See our full provider-focused guide: How to Help Your Patients Find Vigamox in Stock